CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
==== Selachimorpha (True Sharks) ==== Superorder Galeomorphi Order Carcharhiniformes (Ground Sharks) Scyliorhinus torazame, Cloudy catshark (2018) Order Lamniformes (Mackerel Sharks) Carcharodon carcharias, Great white shark (2018) Order Orectolobiformes (Carpet Sharks) Chiloscyllium plagiosum, Whitespotted bamboo shark (2020) Chiloscyllium punctatum, Brownbanded bamboo shark (2018) Rhincodon typus, Whale shark (2017)
Lucilia spp. (green-bottle fly) Cochliomyia spp. (screw-worm fly) Phormia spp. (black-bottle fly) Calliphora spp. (blue-bottle fly) Sarcophaga spp. (flesh fly or sarcophagids) Flesh flies, or sarcophagids, members of the family Sarcophagidae, can cause intestinal myiasis in humans if the females deposit larvae on meat or fruit.
=== Periodicals === International Journal of Food Microbiology Foodborne Pathogens and Disease, ISSN 1535-3141, Mary Ann Liebert, Inc. Mycopathologia, ISSN 1573-0832 (electronic), ISSN 0301-486X (paper), Springer
Sources: en.wikipedia.org
=== NAADP inhibitors === Back in 2009, a selective cell-permeant NAADP antagonist, trans-Ned-19 was discovered which blocks Ca2+ signals and downstream Ca2+-dependent processes such as differentiation. Prior to that, only high concentrations of blockers of L-type Ca2+ channels (e.g. diltiazem, dihydropyridines) could be used (with obvious concerns over non-NAADP effects). A minor modification of Ned-19 produced another, more soluble antagonist, Ned-K. Although not true antagonism, the NAADP 'receptor' can self-inactivate when bound to non-releasing concentrations of NAADP itself. Such inactivating pre-pulses of NAADP were the first strategy for implicating NAADP in subsequent physiological pathways.
Diagnosis is made with reasonable certainty based on history and clinical examination. X-rays may confirm the diagnosis. The typical changes seen on X-ray include: joint space narrowing, subchondral sclerosis (increased bone formation around the joint), subchondral cyst formation, and osteophytes. The combination of knee pain and osteophytes on x-ray or hip pain and osteophytes on x-ray, has good sensitivity and specificity for the diagnosis of osteoarthritis of those joints. X-rays may not correlate with the findings on physical examination or with the degree of pain, especially in the early course of osteoarthritis, where imaging findings may be relatively normal. In 1990, the American College of Rheumatology, using data from a multi-center study, developed a set of criteria for the diagnosis of hand osteoarthritis based on hard tissue enlargement and swelling of certain joints. These criteria were found to be 92% sensitive and 98% specific for hand osteoarthritis versus other entities such as rheumatoid arthritis and spondyloarthropathies.
The origins of the concept of hotspots lie in the work of J. Tuzo Wilson, who postulated in 1963 that the formation of the Hawaiian Islands resulted from the slow movement of a tectonic plate across a hot region beneath the surface. It was later postulated that hotspots are fed by streams of hot mantle rising from the Earth's core–mantle boundary in a structure called a mantle plume. Whether or not such mantle plumes exist has been the subject of a major controversy in Earth science, but seismic images consistent with evolving theory now exist. At any place where volcanism is not linked to a constructive or destructive plate margin, the concept of a hotspot has been used to explain its origin. A review article by Courtillot et al. listing possible hotspots makes a distinction between primary hotspots coming from deep within the mantle and secondary hotspots derived from mantle plumes. The primary hotspots originate from the core/mantle boundary and create large volcanic provinces with linear tracks (Easter Island, Iceland, Hawaii, Afar, Louisville, Reunion, and Tristan confirmed; Galapagos, Kerguelen and Marquersas likely). The secondary hotspots originate at the upper/lower mantle boundary, and do not form large volcanic provinces, but island chains (Samoa, Tahiti, Cook, Pitcairn, Caroline, MacDonald confirmed, with up to 20 or so more possible). Other potential hotspots are the result of shallow mantle material surfacing in areas of lithospheric break-up caused by tension and are thus a very different type of volcanism.
==== Bapineuzumab ==== Bapineuzumab, a humanized anti-Aβ mAb, is directed against the N-terminus of Aβ. Phase II clinical trials of Bapineuzumab in mild to moderate AD patients resulted in reduced Aβ concentration in the brain. However, in patients with increased apolipoprotein (APOE) e4 carriers, Bapineuzumab treatment is also accompanied by vasogenic edema, a cytotoxic condition where the blood brain barrier has been disrupted thereby affecting white matter from excess accumulation of fluid from capillaries in intracellular and extracellular spaces of the brain. In Phase III clinical trials, Bapineuzumab showed promising positive effect on biomarkers of AD but failed to show effect on cognitive decline. Therefore, Bapineuzumab was discontinued after failing in the Phase III clinical trial.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.